埃罗妥珠单抗联合泊马度胺和地塞米松治疗复发/难治性多发性骨髓瘤:随机II期ELOQUENT-3试验最终总生存分析
ELOQUENT-3 II期随机试验纳入117例既往接受来那度胺和蛋白酶体抑制剂治疗且对末次治疗难治的复发/难治性多发性骨髓瘤患者,按1:1随机接受EPd或Pd方案。最终分析显示EPd组中位总生存29.8个月,Pd组17.4个月,风险比0.59(95%CI 0.37-0.93;P=0.0217),差异有统计学意义;安全性特征与既往报告一致,未发现新安全性信号。
要点
- EPd组中位OS为29.8个月,Pd组为17.4个月,HR 0.59(95%CI 0.37-0.93;P=0.0217)。
- EPd组死亡37例(61.7%),Pd组死亡41例(74.5%),多数因疾病进展死亡。
- EPd安全性特征与既往报告一致,未发现新安全性信号。
核心结论
- 在既往接受来那度胺和蛋白酶体抑制剂治疗且对末次治疗难治的复发/难治性多发性骨髓瘤患者中,EPd较Pd显著改善总生存。
- ELOQUENT-3是首个显示含单克隆抗体联合泊马度胺和地塞米松的三药方案同时显著改善PFS和OS的随机研究。
研究设计与样本
- II期ELOQUENT-3随机试验(ClinicalTrials.gov标识符NCT02654132),共随机分配117例患者至EPd组(n=60)和Pd组(n=57)。
- 纳入既往接受≥2线治疗、对末次治疗难治且对来那度胺和蛋白酶体抑制剂难治或复发且难治的复发/难治性多发性骨髓瘤患者,按1:1随机分配。
- 主要终点为研究者评估的PFS,ORR和OS为计划按层级检验的次要终点。
主要发现
- 可评估患者中(EPd 60例,Pd 55例),EPd组死亡37例(61.7%),Pd组死亡41例(74.5%),最常见死因为疾病进展(EPd 41.7%,Pd 49.1%)。
- EPd组中位OS为29.8个月(95%CI 22.9-45.7),Pd组为17.4个月(95%CI 13.8-27.7),HR 0.59(95%CI 0.37-0.93;P=0.0217)。
- EPd的OS获益在大多数患者亚组中均可观察到。
关键数值与推荐
- EPd组中位OS 29.8个月(95%CI 22.9-45.7)vs Pd组17.4个月(95%CI 13.8-27.7),HR 0.59(95%CI 0.37-0.93;P=0.0217)。
- EPd组死亡37例(61.7%)vs Pd组死亡41例(74.5%)。
- 疾病进展所致死亡:EPd组41.7% vs Pd组49.1%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: In the phase II ELOQUENT-3 trial (ClinicalTrials.gov identifier: NCT02654132), elotuzumab combined with pomalidomide/dexamethasone (EPd) significantly improved progression-free survival (PFS) versus pomalidomide/dexamethasone (Pd) in patients with relapsed/refractory multiple myeloma (RRMM) previously treated with lenalidomide and a proteasome inhibitor (PI). Here, we present the final overall survival (OS) results. METHODS: Patients with RRMM who had received ≥ 2 prior lines of therapy, with disease refractory to last therapy and either refractory or relapsed and refractory to lenalidomide and a PI were randomly assigned (1:1) to receive EPd or Pd. The primary end point was PFS per investigator assessment. ORR and OS were secondary end points planned to be tested hierarchically. RESULTS: A total of 117 patients were randomly assigned to EPd (n = 60) and Pd (n = 57). Among treated patients (EPd 60, Pd 55), there were 37 (61.7%) deaths in the EPd group and 41 (74.5%) in the Pd group, most commonly because of disease progression (EPd 41.7%, Pd 49.1%). Median (95% CI) OS was significantly improved with EPd (29.8 [22.9 to 45.7] months) versus Pd (17.4 [13.8 to 27.7] months), with a hazard ratio of 0.59 (95% CI, 0.37 to 0.93; P = .0217). OS benefit with EPd was observed in most patient subgroups. The safety profile of EPd was consistent with prior reports with no new safety signals detected. CONCLUSION: EPd demonstrated a statistically significant improvement in OS versus Pd in patients with RRMM previously treated with lenalidomide and a PI who had disease refractory to last therapy. In this setting, ELOQUENT-3 is the first randomized study of a triplet regimen incorporating a monoclonal antibody and Pd to improve both PFS and OS significantly.
引用
- Dimopoulos MA, Dytfeld D, Grosicki S, et al. Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial. J Clin Oncol. 2022. PMID: 35960908. doi:10.1200/JCO.21.02815
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。